Ó£»¨ÊÓƵ

Verstraeten T

2008 [27]

Belgium

Cohort

HPV vaccine

68,512 participants involved in adjuvanted vaccines of AS04

RR

1.78 years (mean)

adolescents and young adults

/

Bengtsson C

2010 [31]

Sweden

Case-control

Influenza

vaccine

1,998 incident cases of RA and 2,252 randomly selected controls matched for age, sex, and residency.

OR

5 years

18–70

Age, sex, and residency zone

Ray P

2011 [23]

USA

Cohort

Tetanus vaccine;

Influenza vaccine; HBV vaccine

2,587,199 participants aged 15–59 years from 1997 through 1999

RR

2 years

15–19

Race, sex, and exact number of utilization visits.

Chao C

2012 [30]

USA

Cohort

HPV vaccine

189,629 women who received at least one dose of HPV vaccine between 2006 and 2008

RR

0.49 years

9–26

Age.

Ho TY 2012 [29]

Taiwan

Cohort

Influenza vaccine

41,986 vaccinated elderly persons and 50,973 unvaccinated elderly persons

OR

1 years

65–80+

Gender, age, comorbidity, geographic region and urbanization of residence, and individual socioeconomic status.

Arnheim-Dahl strom L2013 [33]

Sweden

Cohort

HPV vaccine

997,585 girls and 296,826 of them

received HPV vaccines

RR

4.17 years

10–18

Country, age, calendar year, parental educational level, parental country of birth, and paternal socioeconomic status.

Angelo MG 2014 [34]

Belgium

Cohort

HPV vaccine

31,173 adolescent girls and adult women receiving HPV vaccine and 24,241 controls

RR

3.25 years

9–26+

/

Persson I 2014 [22]

Sweden

Cohort

Influenza

Vaccine

vaccination with Pandemrix

3,347,467 were vaccinated with Pandemrix between 2009 and 2010 and 2,497,572 non-vaccinated individuals.

HR

2.25 years

0–80+

County of residence, age, gender, education, income, birthplace, number of hospitalizations, and number of ambulatory care visits.

Vaughn DW

2014 [28]

Belgium

Cohort

Influenza vaccine

22,521 participants

RR

3 years for vaccine recipients;

0.5 years for control recipients.

44.0 ± 18 0.1

age, gender, race

Lai YC 2015 [21]

USA

Case-control

Herpes Zoster vaccine

140 RA patients and 448 controls

RR

9.5 years

/

/

Bardenheier

BH 2016 [32]

USA

Case-control

Anthrax Vaccine

77 RA patients and 229 controls

OR

2.75 years

18–45+

Sex, age, service branch, calendar time of beginning under medical surveillance, and deployment status.

Geier DA 2016 [19]

USA

Case-control

HPV vaccine

43 RA patients and 48,809 controls

OR

9 years

6–39

/

Geng Y 2023 [20]

China

Cohort

COVID-19 vaccine

[Sinovac (70, 67.3%)

Sinopharm (27, 26.0%)

followed by recombinant subunit vaccine from Zhifei Longcom (7, 6.7%)]

98 patients received no vaccine shot and 104 patients received two doses of vaccine

OR

1.08 years

vaccination group: 51.6 ± 14.0

non-vaccination group: 55.5 ± 13.0

Female, Age (years), Disease duration (years), Body mass index (kg/m2), Smoking history, Comorbidities

Ju H J 2023 [25]

Korea

Cohort

COVID-19 vaccine

(BNT162b2

mRNA-1273)

Individuals who received vaccination:3,838,120. Historical prepandemic controls were matched for age and sex in a 1:1 ratio: of 3,834,804.

HR

Vaccination cohort:0.28 ± 0.25 years; historical cohort:0.28 ± 0.24 years.

³Õ²¹³¦³¦¾±²Ô²¹³Ù¾±´Ç²Ô:45.7 ±â¶Ä‰18.7;

Historical control:44.8 ± 18.7

Age, Sex, Insurance type, Income level, Location of residence, Underlying disease

Yang G 2023 [26]

China

Cohort

HPV vaccine

After the propensity score matching, the vaccinated group was 497; and the unvaccinated group was 497.

RR

9 years

³Õ²¹³¦³¦¾±²Ô²¹³Ù±ð»å:28.21 ±â¶Ä‰8.56

±«²Ô±¹²¹³¦³¦¾±²Ô²¹³Ù±ð»å:28.27 ±â¶Ä‰8.12

age, sex, race, education level, marital status, smoking, diabetes, hypertension, hyperlipidemia, and Body mass index (BMI)

Jung SW

2024 [24]

Korea

Cohort

COVID-19 vaccine

(BNT162b2, Pfizer–BioNTech vs. mRNA-1273, Moderna)

In total, 4,445,333

and 4,444,932 patients were included in the vaccination and historical

control cohorts, respectively.

HR

Vaccination cohort:1.29 ± 0.18 years; historical control cohor: 1.29 ± 0.18 years.

³Õ²¹³¦³¦¾±²Ô²¹³Ù¾±´Ç²Ô:53.42 ±â¶Ä‰14.19;

Historical control: 51.42 ± 14.19

Age, Sex, Insurance type, Area of residence, Underlying disease, Income level quartile